Biopharma industry confidence at highest in years despite geopolitical headwinds
Biopharma executives’ confidence in the industry has reached its highest point in four years, reflecting a successful navigation through a…
19 Jun 2026
Voro and Alloy partner on tumour-selective TCE therapeutics
Voro Therapeutics and Alloy Therapeutics have formed a strategic research partnership to develop tumour-selective, next-generation masked T-cell engager (TCE) therapeutics. The partnership will bring together Voro Therapeutics’ tumour-activated biologics platform…
19 Jun 2026
Biogen to acquire RayThera for up to $1bn
Biogen has entered a definitive agreement to acquire RayThera, a biotechnology company specialising in small-molecule therapies for immunology, for up to $1bn. The deal value comprises an upfront payment and…
18 Jun 2026
UniQure to seek approval of Huntington’s gene therapy after FDA U-turn
UniQure has confirmed it will submit its Huntington’s disease gene therapy for regulatory review, after the US Food and Drug Administration (FDA) rescinded previous demands for extra clinical data. If…
18 Jun 2026
Jazz and AbCellera sign deal for T-cell engagers in solid tumours
Jazz Pharmaceuticals and AbCellera have signed a preclinical research, option, and licence agreement for the discovery and development of T-cell-engaging multispecific antibodies, or T-cell engagers (TCEs), for gastrointestinal (GI) cancers…
18 Jun 2026
LG AI Research and D&D Pharmatech sign agreement for oral peptide drugs
LG AI Research and D&D Pharmatech have entered an agreement to collaborate on the development of next-generation oral peptide drugs, the companies announced following a signing ceremony held at the…
17 Jun 2026
Biopharma bounces back as M&A impetus fuels recovery
Following the largest dealmaking quarter in six years, PwC analysts have empirically stated that the biopharma ecosystem is “back to full health”. In its midyear outlook report, the firm stated…